Clinical Trial Update: FES PET/CT in Predicting Response in Patients With Newly Diagnosed Metastatic Breast Cancer Receiving Endocrine Therapy [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating Fluoroestradiol PET/CT to predict response to endocrine therapy in newly diagnosed metastatic breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: HER2/Neu Negative, Progesterone Receptor Negative | Phase 2 | Status: ACTIVE_NOT_RECRUITING